Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
338 Leser
Artikel bewerten:
(1)

Net Medical Xpress Solutions, Inc.: Net Medical to Launch New Supplement Line to Boost Immune Systems; Specifically Targets Colds, Flu, Inflammation and Cell Mutations

Leaning on two decades of experience connecting providers with the patients who need them, Net Medical's business is unique and growing

ALBUQUERQUE, NM / ACCESSWIRE / February 28, 2022 / Net Medical (OTC PINK:NMXS) announced today it is launching a new supplements product line under the brand Immunity Science offering vitamins to boost immune systems.

Immunity Science will offer several anti-inflammatory supplements along with a specialized product line of gummies that will be sold on the website https://www.immunityscience.store. The website is expected to be launched by the end of March.

The new line will include zinc, quercetin and vitamins C and D. Multiple studies have shown these supplements can be effective in supporting the immune system against inflammation and common viruses such as colds, flu and similar illnesses. Quercetin has been shown to reduce the risk of infection and inflammation. A recent Israeli study showed that Vitamin D can reduce the risk or serious illness or death from Covid-19. Zinc has been described as the bullet against Covid-19.

Other products for anti-inflammatory conditions will include Irish Sea Moss. The Immunity Science Sea Moss grows naturally along the Atlantic shorelines of Europe and America. It's been described as a superfood of the sea. It's used for easing joint pain, boosting metabolism and supports the immune system and fights infection.

Net Medical CEO Dick Govatski said, "The Covid pandemic has created new awareness about both the need and ability of individuals to take steps to protect their own health. The rapid growth of our Covid testing business has introduced us to a large underserved market of consumers who have a fresh awareness of the threats to their health.

Consumers want more specific help in strengthening their bodies against inflammation, colds and flu, but current products are often confusing or even misleading. We believe our new Immunity Science product line will be well received and make an important contribution to the health and well-being of our customers."

For more information, call 505-255-1999. X 320. Visit www.netmedical.com. Email ir@netmedical.com

About Net Medical - publicly traded (OTC Pink:NMXS) since 1999.

Net Medical Xpress has two operating units. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. The company specializes in teleneurology, teleneurosurgery, telecardiology, teleorthopedics, telewoundcare and telenephrology. We maintain a 24/7/365 call center, software developers, and telemedicine platforms. In additional, Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus testing and diagnostics. The company's mobile fleet of vans is utilized to provide statewide COVID and FLU testing for schools, companies, homeless shelters, and nursing homes. The lab also serves as a reference lab for physician offices, and other facilities that lack services for complex virus diagnostics.

Forward-Looking Statements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are the company's current expectations about future events and can be identified by terms such as "plans," "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "believes," and similar expressions referring to future periods. The company believes any expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements.

SOURCE: Net Medical Xpress Solutions, Inc.



View source version on accesswire.com:
https://www.accesswire.com/690615/Net-Medical-to-Launch-New-Supplement-Line-to-Boost-Immune-Systems-Specifically-Targets-Colds-Flu-Inflammation-and-Cell-Mutations

© 2022 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.